
Epigenomics AG
Epigenomics AG (EPGNF) PE Ratio — Current & Historical Data
Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.
epgnf · pe ratio · data through Jun 9, 2026
Core PE Ratio Metrics
Trailing 12 months · TTMInsufficient PE history data (fewer than 3 valid fiscal years).
PE Ratio vs Peers
Medical - Diagnostics & Research · 4 peers · Annual PE| Company | Market Cap | PE (Annual) | vs Avg | EPS (TTM) |
|---|---|---|---|---|
Epigenomics AGYou EPGNF | $1M | N/A | — | -$2.96 |
Body and Mind Inc. BMMJ | $0M | N/A | — | -$0.16 |
Health Logic Interactive Inc. CHYPF | $0M | N/A | — | -$0.01 |
Next Generation Management Corp. NGMC | $0M | N/A | — | -$325.72 |
Procyon Corporation PCYN | $2M | 45.64x | — | $0.00 |
* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio
About PE Ratio & Methodology
The price-to-earnings (P/E) ratio for Epigenomics AG (EPGNF) measures how much investors pay for each dollar of the company's trailing earnings. EPGNF's current PE ratio of N/A is calculated by dividing its stock price of $1.12 by its TTM earnings per share of -$2.96.
Frequently asked questions
EPGNF pe ratio · 6 questionsEPGNF's current PE ratio is N/A as of 2026-06-09, based on a stock price of $1.12 and TTM EPS of -$2.96. Data sourced from Financial Modeling Prep via EPGNF's SEC 10-K and 10-Q filings.
▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · Epigenomics AG SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-09